Congenital toxoplasmosis: Efficacy of maternal treatment with spiramycin alone

American Journal of Reproductive Immunology

Volumn 39, Issue 5, 1998, Pages 335-340

  Vergani, Patrizia ^a   Ghidini, Alessandro ^a,b   Ceruti, Patrizia ^a   Strobelt, Nicola ^a   Spelta, Antonella ^a   Zapparoli, Barbara ^a   Rescaldani, Roberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Congenital infection; Fetal therapy; Prenatal diagnosis; Toxoplasmosis

Indexed keywords

PYRIMETHAMINE; SPIRAMYCIN; SULFONAMIDE;

BRAIN CALCIFICATION; BRAIN MALFORMATION; CONFERENCE PAPER; CONGENITAL INFECTION; CONGENITAL TOXOPLASMOSIS; DRUG EFFICACY; EYE MALFORMATION; FEMALE; FETUS; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PREGNANCY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCAR;

EID: 0031920147     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1998.tb00527.x     Document Type: Conference Paper

References (23)

1. Desmonts G, Couvreur J: Congenital toxoplasmosis: A prospective study of 378 pregnancies. N Engl J Med 1974; 290:1110-1116.
2. Hengst P: Screening for toxoplasmosis in pregnant women: Presentation of a screening program in the former "East" Germany, and the present status in Germany. Scand J Infect Dis 1992; 84 Suppl; 38-42.
3. Daffos F, Forestier F, Capella-Pavlovski M, Thulliez P, Aufrant C, Valenti D, et al.: Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med 1988; 318:271-275.
4. Hohlfeld P, MacAleese J, Capella-Pavlovski M, Giovangrandi Y, Thulliez P, Forestier F, et al.: Fetal toxoplasmosis: Ultrasonographic signs. Ultrasound Obstet Gynecol 1991; 1:241-244.
5. Hohlfeld P, Daffos F, Thulliez P, Aufrant C, Couvreur J, MacAleese J, et al.: Fetal toxoplasmosis: Outcome of pregnancy and infant follow-up after in-utero treatment. J Pediatr 1989; 115:765-769.
6. Couvreur J, Thulliez P, Daffos F, Aufrant C, Bompard Y, Gesquiere A, et al.: In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn Ther 1993; 8:45-50.
7. Rescaldani R, Vezzo R, Bramati S: Metodo automatico MEIA (microparticle enzyme immunoassay) per la ricerca di anticorpi IgG anti- Toxoplasma. Microbiol Medica 1991; 6:162-165.
8. Rescaldani R, Vigore L, Vezzo R: Toxoplasmosi sintomatica e test di avidita' delle IgG. Microbiol Medica 1992; 7:96-98.
9. Lappalainen M, Koskiniemi M, Hiilesmaa V, Ämmälä P, Teramo K, Koskela P, et al.: Outcome of children after maternal primary toxoplasma infection during pregnancy with emphasis on avidity of specific IgG. Pediatr Infect Dis J 1995; 14:354-361.
10. Desmonts G, Couvreur J: Congenital toxoplasmosis: A prospective study of 542 women who acquired toxoplasmosis during pregnancy. Ann Pediatr 1984; 31:805-809.
11. Desmonts G, Daffos F. Forestier F, Capella-Pavlovsky M, Thulliez P, Chartier M: Prenatal diagnosis of congenital toxoplasmosis. Lancet 1985; i:500-504.
12. Berrebi A, Kobuch WE, Bessieres MH, Bloom MC, Rolland MF, Sarramon MF, et al.: Termination of pregnancy for maternal toxoplasmosis. Lancet 1994; 344:36-39.
13. Pratlong F, Boulot P, Issert E, Mskia M, Dupont F, Bachelard B, et al.: Fetal diagnosis of toxoplasmosis in 190 women infected during pregnancy. Prenat Diagn 1994; 14:191-198.
14. Foulon W, Naessens A, Mahler T, De Waele M, De Gatte L, De Meuter F: Prenatal diagnosis of congenital toxoplasmosis. Obstet Gynecol 1990; 76:769-772.
15. Foulon W, Naessens A, Derde MP: Evaluation of the possibilities for preventing congenital toxoplasmosis. Am J Perinatol 1994; 11:57-62.
16. Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M: Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain reaction test on amniotic fluid. N Engl J Med 1994; 331:695-699.
17. Cazenave J, Forestier F. Bessieres MH, Broussin B, Begueret J: Contribution of a new PCR assay to the prenatal diagno- sis of congenital toxoplasmosis. Prenatal Diagn 1992; 12:119-127.
18. Schoondermark-Van de Ven E, Galama J, Camps W, Vree T, Russel F, Meuwissen J, et al.: Pharmacokinetics of spiramycin in the Rhesus monkey: Transplacental passage and distribution in tissue in the fetus. Antimicrob Agents Chemiother 1994; 38:1922-1929.
19. Schoondermark-Van de Ven E, Melchers W, Camps W, Eskes T, Meuwissen J, Galama J: Effectiveness of spiramycin for treatment of congenital toxoplasma gondii infection in Rhesus monkeys. Antimicrob Agents Chemiother 1994; 38:1930-1936.
20. Kavi J, Webberley JM, Andrews JM, Wise R: A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin. J Antimicrob Chemiother 1988; 22 Suppl.B:105-110.
21. Schoondermark-Van de Ven E, Galama J, Vree T, Camps W, Baars I, Eskes T, et al.: Study of treatment of congenital toxoplasma gondii infection in Rhesus monkeys with pyrimethamine and sulfadiazine. Antimicrob Agents Chemiother 1995; 39:137-144.
22. Mansor SM, Navaratnam V, Mohamad M, Hussein S, Kumar A, Jamaludin A, et al,: Single dose kinetic study of the triple combination of mefloquine/sulphadoxine/pyrimethamine (Fanismef) in healthy male volunteers. Br J Clin Pharmacol 1989; 27:381-386.
23. Matsui D: Prevention, diagnosis, and treatment of fetal toxoplasmosis. Clin Perinatol 1994; 21:675-689.